Literature DB >> 10608899

Identification and characterization of a ligand-independent oligomerization domain in the extracellular region of the CD95 death receptor.

G Papoff1, P Hausler, A Eramo, M G Pagano, G Di Leve, A Signore, G Ruberti.   

Abstract

The CD95 death receptor plays an important role in several physiological and pathological apoptotic processes involving in particular the immune system. CD95 ligation leads to clustering of the receptor cytoplasmic "death domains" and recruitment of the zymogen form of caspase-8 to the cell surface. Activation of this protease through self-cleavage, followed by activation of downstream effector caspases, culminates in cleavage of a set of cellular proteins resulting in apoptosis with disassembly of the cell. It is very well known that the extracellular region of the CD95 receptor is required for CD95L interaction and that the death domain is necessary for the induction of the apoptotic signaling. Here, we identified and characterized a novel CD95 ligand- and death domain-independent oligomerization domain mapping to the NH(2)-terminal extracellular region of the CD95 receptor. In vitro and in vivo studies indicated that this domain, conserved among all soluble CD95 variants, mediates homo-oligomerization of the CD95 receptor and of the soluble CD95 proteins, as well as hetero-oligomerization of the receptor with the soluble variants. These results offer new insight into the mechanism of apoptosis inhibition mediated by the soluble CD95 proteins and suggest a role of the extracellular oligomerization domain in the regulation of the non-signaling state of the CD95 receptor.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10608899     DOI: 10.1074/jbc.274.53.38241

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  39 in total

1.  A fifteen-amino-acid TVB peptide serves as a minimal soluble receptor for subgroup B avian leukosis and sarcoma viruses.

Authors:  Daniel J Knauss; John A T Young
Journal:  J Virol       Date:  2002-06       Impact factor: 5.103

2.  Organization and dynamics of Fas transmembrane domain in raft membranes and modulation by ceramide.

Authors:  Bruno M Castro; Rodrigo F M de Almeida; Erik Goormaghtigh; Aleksander Fedorov; Manuel Prieto
Journal:  Biophys J       Date:  2011-10-05       Impact factor: 4.033

3.  Signaling active CD95 receptor molecules trigger co-translocation of inactive CD95 molecules into lipid rafts.

Authors:  Isabell Lang; Andrea Fick; Viktoria Schäfer; Tina Giner; Daniela Siegmund; Harald Wajant
Journal:  J Biol Chem       Date:  2012-05-29       Impact factor: 5.157

4.  Unleashing cell death: the Fas-FADD complex.

Authors:  Sarah G Hymowitz; Vishva M Dixit
Journal:  Nat Struct Mol Biol       Date:  2010-11       Impact factor: 15.369

Review 5.  Three is better than one: pre-ligand receptor assembly in the regulation of TNF receptor signaling.

Authors:  Francis Ka-Ming Chan
Journal:  Cytokine       Date:  2007-04-20       Impact factor: 3.861

6.  Dominant negative effects of tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptor 4 on TRAIL receptor 1 signaling by formation of heteromeric complexes.

Authors:  Simon Neumann; Jan Hasenauer; Nadine Pollak; Peter Scheurich
Journal:  J Biol Chem       Date:  2014-04-24       Impact factor: 5.157

7.  Intra- and interdimeric caspase-8 self-cleavage controls strength and timing of CD95-induced apoptosis.

Authors:  Stefan M Kallenberger; Joël Beaudouin; Juliane Claus; Carmen Fischer; Peter K Sorger; Stefan Legewie; Roland Eils
Journal:  Sci Signal       Date:  2014-03-11       Impact factor: 8.192

8.  Molecular ordering of the initial signaling events of CD95.

Authors:  Alicia Algeciras-Schimnich; Le Shen; Bryan C Barnhart; Andrea E Murmann; Janis K Burkhardt; Marcus E Peter
Journal:  Mol Cell Biol       Date:  2002-01       Impact factor: 4.272

9.  Transforming growth factor-beta 1 induces apoptosis through Fas ligand-independent activation of the Fas death pathway in human gastric SNU-620 carcinoma cells.

Authors:  Sang Gyun Kim; Hyun-Soon Jong; Tae-You Kim; Jung Weon Lee; Noe Kyeong Kim; Seung Hwan Hong; Yung-Jue Bang
Journal:  Mol Biol Cell       Date:  2003-10-31       Impact factor: 4.138

Review 10.  The promise and challenges of immune agonist antibody development in cancer.

Authors:  Patrick A Mayes; Kenneth W Hance; Axel Hoos
Journal:  Nat Rev Drug Discov       Date:  2018-06-15       Impact factor: 84.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.